P
rescription drug prices may be rising, but a new analysis suggests just not as fast as before.
Price hikes for brand-name drugs in this year’s second quarter were 7.1 percent. This obviously exceeds inflation and may have crimped some wallets, but this is below the 9.7 percent hikes that occurred in the same period a year earlier, according to SSR Research, which tracks the pharmaceutical industry.
Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
